McKesson Corporation

NYSE:MCK 株式レポート

時価総額：US$90.7b

McKesson 将来の成長

Future 基準チェック /26

McKesson利益と収益がそれぞれ年間8.7%と6.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に138.8% 12.1%なると予測されています。

主要情報

8.7%

収益成長率

12.06%

EPS成長率

Healthcare 収益成長18.3%
収益成長率6.8%
将来の株主資本利益率138.76%
アナリストカバレッジ

Good

最終更新日13 May 2026

今後の成長に関する最新情報

分析記事 • May 11

McKesson Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

McKesson Corporation ( NYSE:MCK ) shareholders are probably feeling a little disappointed, since its shares fell 8.9...

Recent updates

ナラティブの更新 • May 13

MCK: Biosimilar Co Manufacturing Will Shape Future Healthcare Safe Haven Appeal

Analysts have trimmed the McKesson fair value estimate by about $39 to $951.73. This reflects updated views on slightly higher discount rates, a more moderate revenue growth outlook, a small shift in profit margin assumptions, and a lower future P/E multiple after a mix of recent price target increases and cuts across the Street.
分析記事 • May 11

McKesson Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

McKesson Corporation ( NYSE:MCK ) shareholders are probably feeling a little disappointed, since its shares fell 8.9...
Seeking Alpha • May 01

McKesson - "Hold" Still Valid In 2026

Summary McKesson (MCK) is a fundamentally strong, market-leading distributor but faces mounting structural risks in the US healthcare sector. I see current valuation—over 21x P/E—as unattractive, with upside limited by regulatory, pricing, and margin pressures. Much of MCK's recent growth stems from high-priced drugs and GLP-1 revenues, which may plateau and expose underlying business vulnerabilities. I assign MCK a 'Hold' rating with a $510/share price target, citing insufficient risk/reward at present levels. Read the full article on Seeking Alpha
ナラティブの更新 • Apr 27

MCK: Biosimilar Co Manufacturing Will Shape Future Healthcare Safe Haven Appeal

McKesson's analyst price target has been trimmed slightly, with the fair value estimate edging down by about $1 to $990.87 as analysts factor in recent target cuts alongside ongoing interest in the company's biosimilar and distribution opportunities. Analyst Commentary Recent research on McKesson has centered on how much value the market is assigning to its biosimilar pipeline, distribution scale and perceived defensiveness within healthcare, with a mix of higher and lower price targets reflecting different views on execution risk and current valuation.
ナラティブの更新 • Apr 10

MCK: Biosimilar Co Manufacturing Optionality Will Shape Future Safe Haven Appeal

McKesson's analyst-derived fair value estimate has been adjusted slightly lower, from about $997.67 to $991.67. Analysts are weighing recent trims to Street price targets and fresh caution around premium valuation against prior enthusiasm for biosimilar optionality and healthcare defensiveness.
ナラティブの更新 • Mar 27

MCK: Biosimilar And Co Manufacturing Upside Will Shape Future Safe Haven Returns

Analysts have nudged the McKesson fair value estimate slightly higher to about $998, citing a wave of Street price target increases into the $1,040 to $1,050 range and growing focus on potential upside from biosimilars and co-manufacturing. Analyst Commentary Recent Street research around McKesson clusters around two themes: valuation and execution on new growth levers such as biosimilars and co-manufacturing.
ナラティブの更新 • Mar 11

MCK: Biosimilar Optionality And Premium Safe Haven Position Will Shape Future Returns

Analysts have increased their McKesson price target from $980.40 to $995.27, citing higher Street targets that reflect new biosimilar optionality and continued interest in the stock as a perceived healthcare safe haven, even at a premium valuation. Analyst Commentary Bullish analysts are leaning into McKesson's role as a perceived healthcare safe haven and the new biosimilar angle, using these themes to justify higher valuation levels than the recent three year average.
ナラティブの更新 • Feb 24

MCK: Defensive Healthcare Premium And Buybacks Will Shape Perceived Safety Trade

Analysts have raised McKesson's fair value estimate by about $14 to $980.40, as a series of higher Street price targets, including Barclays' move to $1,050, keeps the stock in focus for investors seeking perceived safety within healthcare, even as shares trade at a premium to recent averages. Analyst Commentary Recent research has centered on McKesson's valuation after a series of price target increases, including a move to US$1,050 that highlights how closely investors are watching the name as a perceived defensive healthcare holding.
ナラティブの更新 • Feb 09

MCK: Refined Assumptions And Supportive Policy Backdrop Will Shape FY26 AOI

The McKesson analyst price target has been raised by about $24 to $966, with analysts pointing to updated fair value work, modest adjustments to the discount rate and growth assumptions, and slightly higher future P/E expectations as key drivers of the change. Analyst Commentary Recent Street research on McKesson clusters around higher price targets and refreshed valuation work, with analysts fine tuning assumptions on growth, discount rates and future P/E multiples.
ナラティブの更新 • Jan 26

MCK: North American Pharma Momentum And Supportive Policy Backdrop Will Drive FY26 AOI

Narrative Update The analyst price target for McKesson has been raised by roughly $3 to $942.00, as analysts point to steady assumptions for revenue growth, margins and P/E, along with supportive views on North American Pharma momentum, a constructive industry demand backdrop, and the absence of new onerous proposals in recent healthcare policy commentary. Analyst Commentary Recent research on McKesson is broadly constructive, with several firms lifting their price targets and pointing to supportive sector trends and company specific drivers.
ナラティブの更新 • Jan 12

MCK: North American Pharma Strength Will Support FY26 Core AOI Framework

Narrative Update: McKesson Analysts have lifted their McKesson price targets toward a range of about $900 to $1,000, citing solid North American Pharma momentum, modeled core AOI growth of around 7% for FY26, and a robust demand backdrop reflected in peers' recent results. Analyst Commentary Recent research updates reflect a more constructive stance on McKesson, with higher price targets tied to underlying business trends and peer readthroughs rather than short term trading factors.
ナラティブの更新 • Dec 18

MCK: North American Pharma Momentum Will Drive Future EPS Framework Confidence

Our McKesson narrative fair value has increased modestly to approximately $939 per share from about $935, reflecting analysts' higher price targets and conviction in sustained EPS growth, improved North American Pharma momentum, and a more robust valuation framework supported by stronger industry demand trends. Analyst Commentary Street research sentiment on McKesson remains skewed positive, with a broad wave of price target increases reflecting higher conviction in the companys ability to deliver on its upgraded long term earnings framework and FY26 guidance.
ナラティブの更新 • Dec 03

MCK: North American Pharma Momentum Will Drive Future Outlook Amid Policy Uncertainty

We modestly raise our McKesson fair value estimate to about $934.79 per share from roughly $934.71, reflecting analysts' higher price targets, stronger confidence in long term EPS growth, and sustained North American Pharma momentum. Analyst Commentary Street research on McKesson has turned increasingly constructive, with multiple firms lifting price targets in response to upgraded long term guidance, stronger segment momentum, and enhanced disclosure following the recent investor day.
ナラティブの更新 • Nov 19

MCK: Future Execution and Pharma Trends Will Shape Outlook Amid Policy Uncertainty

McKesson's analyst price target has been raised significantly, increasing by nearly $90 per share to $934.71. Analysts cite strong momentum in North American Pharma, higher long-term EPS guidance, and robust industry trends supporting continued growth.
ナラティブの更新 • Nov 05

MCK: Future Demand and Oncology Distribution Will Set the Earnings Outlook

McKesson’s analyst price target has increased from approximately $837 to $845. Analysts cite robust demand, industry-wide utilization trends, and the company’s strengthened long-term earnings outlook as key factors supporting the upward revision.
ナラティブの更新 • Oct 22

Analysts Boost McKesson Outlook Amid Strong Growth Guidance and Recent Valuation Adjustments

Analysts have raised their average fair value estimate for McKesson to $836.71 from $829.57. This change is attributed to increased long-term growth guidance and improved business visibility following the company’s recent investor day.
ナラティブの更新 • Oct 08

Pharmaceutical Demand And Digital Automation Will Shape Future Markets

McKesson's analyst fair value estimate has been raised from $793.21 to $829.57. This increase reflects higher price targets, driven by analysts who cite upgraded long-term growth guidance and strengthened expectations following recent investor presentations.
ナラティブの更新 • Sep 24

Pharmaceutical Demand And Digital Automation Will Shape Future Markets

McKesson’s fair value saw only a marginal increase as analyst expectations for both revenue growth and net profit margin remained virtually unchanged, with the target price moving slightly from $788.57 to $793.21. What's in the News Playhouse MD™, a pediatric healthcare brand, has entered a strategic distribution alliance with McKesson Medical-Surgical, making its products available nationwide and expanding McKesson's portfolio in pediatric care.
分析記事 • Jul 07

Why Investors Shouldn't Be Surprised By McKesson Corporation's (NYSE:MCK) P/E

With a price-to-earnings (or "P/E") ratio of 27.3x McKesson Corporation ( NYSE:MCK ) may be sending bearish signals at...
Seeking Alpha • Mar 25

McKesson: Immune To Weak Economy And Tariffs; Top Idea In 2025

Summary I maintain a 'Strong Buy' rating on McKesson with a fair value of $723 per share due to its robust oncology network and strong growth prospects. McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability, making it a reliable investment amid economic uncertainties. The company's GLP-1 and oncology franchises are key growth drivers, with GLP-1 revenue growing 45% year-over-year and oncology patient visits increasing steadily. Despite potential tariff-related risks in the biotech sector, McKesson's strong performance and strategic guidance make it a safe haven for investors in 2025. Read the full article on Seeking Alpha
Seeking Alpha • Jan 21

McKesson Seems Cheap, But Risks Linger

Summary McKesson's stock appears undervalued, trading at 18 times forward earnings and free cash flow, despite recent price increases and solid growth prospects in oncology and GLP-1 medications. Quarterly results show mixed performance, with revenue up 21.3% YoY but operating income and EPS down; adjusted EPS grew 13.5% YoY. Risks include political pressures on drug pricing, competition from vertically integrated healthcare providers like CVS and Amazon, and potential recession impacts. Despite bullish arguments and recession resilience, I rate McKesson as a 'Hold' due to high recession risk and a cautious market outlook. Read the full article on Seeking Alpha
Seeking Alpha • Nov 09

McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network

Summary I reiterate a 'Strong Buy' on McKesson, driven by growth from GLP-1 medications and a robust oncology network business, with a fair value of $696 per share. McKesson's acquisition of a 70% interest in Florida Cancer Specialists enhances its oncology network, expanding to 3,300 providers across 31 states. Strong Q2 results with 21% revenue growth and raised EPS guidance to $32.40-$33.00, driven by specialty distribution and retail national account customers. Future growth driven by GLP-1 medications, oncology network expansion, and margin improvements, despite weak growth in Medical surgical solutions post-Covid. Read the full article on Seeking Alpha
Seeking Alpha • Oct 09

McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff

Summary Healthcare is a great defensive sector that has lower amounts of cyclicality than others that depend on the booming economy. With the stock currently down -21.44% off of its all-time high, the stock is giving investors a nice entry point as it reverts to the mean S&P500 returns. The company was the highest-scoring large cap on the most recent Magic Formula screen for October 2024. The Healthcare distribution sub-sector provides exposure to big Pharma without the patent cliffs. Read the full article on Seeking Alpha
Seeking Alpha • Sep 10

McKesson: The Correction Is Not Over

Summary McKesson declined about 20% in the last few weeks and sentiment suddenly turned. Of course, McKesson is performing hand-in-hand with the overall market and we can expect that McKesson will continue to decline - similar to the overall market. On the other hand, we can argue that McKesson is already undervalued a bit, but I still think the stock will continue to decline further due to the overall sentiment. Read the full article on Seeking Alpha
Seeking Alpha • Jul 04

McKesson Corporation: An Interesting Health Giant With A Hidden Gem

Summary McKesson Corporation is a large player in the medical space, with a market capitalization of $75.86 billion. The company has shown attractive top-line growth, but bottom-line results have been disappointing. The most interesting segment of the business is the Prescription Technology Solutions segment, showing impressive growth and profitability. Read the full article on Seeking Alpha

業績と収益の成長予測

NYSE:MCK - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
3/31/2029499,3256,0516,5547,46911
3/31/2028463,9395,4246,0987,01415
3/31/2027431,6464,9264,6875,54315
3/31/2026403,4304,7625,4106,155N/A
12/31/2025397,9584,3409,64410,482N/A
9/30/2025387,0944,0336,0086,867N/A
6/30/2025377,5953,1645,6666,547N/A
3/31/2025359,0513,2955,2266,085N/A
12/31/2024344,5832,8261,6342,484N/A
9/30/2024330,1872,5364,3135,121N/A
6/30/2024313,7512,9593,2563,986N/A
3/31/2024308,9513,0023,6274,314N/A
12/31/2023301,5062,9982,8923,492N/A
9/30/2023291,0983,4874,3064,906N/A
6/30/2023284,0403,7554,4665,048N/A
3/31/2023276,7113,5634,6015,159N/A
12/31/2022273,9033,1464,1904,721N/A
9/30/2022272,0272,0613,9524,430N/A
6/30/2022268,4461,3964,6395,115N/A
3/31/2022263,9661,1193,8994,434N/A
12/31/2021257,0061,4154,3234,917N/A
9/30/2021250,991-4,8044,0984,753N/A
6/30/2021245,223-4,4943,2993,982N/A
3/31/2021238,228-4,5383,9014,542N/A
12/31/2020237,621-4,1895,2315,826N/A
9/30/2020234,1942,2283,9054,492N/A
6/30/2020231,0029222,8513,363N/A
3/31/2020231,0519063,8684,374N/A
12/31/2019224,945-905N/A3,615N/A
9/30/2019221,981-626N/A3,559N/A
6/30/2019217,440601N/A5,046N/A
3/31/2019214,31933N/A4,036N/A
12/31/2018213,518-319N/A3,165N/A
9/30/2018210,927113N/A3,324N/A
6/30/2018209,913-384N/A2,543N/A
3/31/2018208,35762N/A4,345N/A
12/31/2017205,4424,805N/A2,756N/A
9/30/2017201,9554,539N/A3,155N/A
6/30/2017199,8514,846N/A3,626N/A
3/31/2017198,5335,194N/A4,744N/A
12/31/2016196,4982,051N/A6,415N/A
9/30/2016194,2672,044N/A5,349N/A
6/30/2016193,0712,359N/A5,077N/A
3/31/2016190,8842,290N/A3,672N/A
12/31/2015189,1312,237N/A2,449N/A
9/30/2015187,7162,090N/A4,198N/A
6/30/2015183,1151,950N/A3,384N/A

アナリストによる今後の成長予測

収入対貯蓄率: MCKの予測収益成長率 (年間8.7% ) は 貯蓄率 ( 3.5% ) を上回っています。

収益対市場: MCKの収益 ( 8.7% ) US市場 ( 16.7% ) よりも低い成長が予測されています。

高成長収益: MCKの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: MCKの収益 ( 6.8% ) US市場 ( 11.7% ) よりも低い成長が予測されています。

高い収益成長: MCKの収益 ( 6.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MCKの 自己資本利益率 は、3年後には非常に高くなると予測されています ( 138.8 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/21 11:29
終値2026/05/21 00:00
収益2026/03/31
年間収益2026/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

McKesson Corporation 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。33

アナリスト機関
David ToungArgus Research Company
Eric ColdwellBaird
Lawrence MarshBarclays